212 related articles for article (PubMed ID: 24169612)
1. Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial.
Lambers Heerspink HJ; Chertow GM; Akizawa T; Audhya P; Bakris GL; Goldsberry A; Krauth M; Linde P; McMurray JJ; Meyer CJ; Parving HH; Remuzzi G; Christ-Schmidt H; Toto RD; Vaziri ND; Wanner C; Wittes J; Wrolstad D; de Zeeuw D
Nephrol Dial Transplant; 2013 Nov; 28(11):2841-50. PubMed ID: 24169612
[TBL] [Abstract][Full Text] [Related]
2. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.
de Zeeuw D; Akizawa T; Audhya P; Bakris GL; Chin M; Christ-Schmidt H; Goldsberry A; Houser M; Krauth M; Lambers Heerspink HJ; McMurray JJ; Meyer CJ; Parving HH; Remuzzi G; Toto RD; Vaziri ND; Wanner C; Wittes J; Wrolstad D; Chertow GM;
N Engl J Med; 2013 Dec; 369(26):2492-503. PubMed ID: 24206459
[TBL] [Abstract][Full Text] [Related]
3. Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).
de Zeeuw D; Akizawa T; Agarwal R; Audhya P; Bakris GL; Chin M; Krauth M; Lambers Heerspink HJ; Meyer CJ; McMurray JJ; Parving HH; Pergola PE; Remuzzi G; Toto RD; Vaziri ND; Wanner C; Warnock DG; Wittes J; Chertow GM
Am J Nephrol; 2013; 37(3):212-22. PubMed ID: 23467003
[TBL] [Abstract][Full Text] [Related]
4. Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.
Rossing P; Block GA; Chin MP; Goldsberry A; Heerspink HJL; McCullough PA; Meyer CJ; Packham D; Pergola PE; Spinowitz B; Sprague SM; Warnock DG; Chertow GM
Kidney Int; 2019 Oct; 96(4):1030-1036. PubMed ID: 31377056
[TBL] [Abstract][Full Text] [Related]
5. Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.
Chertow GM; Appel GB; Block GA; Chin MP; Coyne DW; Goldsberry A; Kalantar-Zadeh K; Meyer CJ; Molitch ME; Pergola PE; Raskin P; Silva AL; Spinowitz B; Sprague SM; Rossing P
J Diabetes Complications; 2018 Dec; 32(12):1113-1117. PubMed ID: 30318163
[TBL] [Abstract][Full Text] [Related]
6. Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study.
Chin MP; Bakris GL; Block GA; Chertow GM; Goldsberry A; Inker LA; Heerspink HJL; O'Grady M; Pergola PE; Wanner C; Warnock DG; Meyer CJ
Am J Nephrol; 2018; 47(1):40-47. PubMed ID: 29402767
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
Chin MP; Wrolstad D; Bakris GL; Chertow GM; de Zeeuw D; Goldsberry A; Linde PG; McCullough PA; McMurray JJ; Wittes J; Meyer CJ
J Card Fail; 2014 Dec; 20(12):953-8. PubMed ID: 25307295
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.
Chin MP; Reisman SA; Bakris GL; O'Grady M; Linde PG; McCullough PA; Packham D; Vaziri ND; Ward KW; Warnock DG; Meyer CJ
Am J Nephrol; 2014; 39(6):499-508. PubMed ID: 24903467
[TBL] [Abstract][Full Text] [Related]
9. Increased albuminuria in bardoxolone methyl-treated type 2 diabetes patients: mere reflection of eGFR improvement?
Ito M; Nangaku M
Kidney Int; 2019 Oct; 96(4):823-825. PubMed ID: 31543152
[TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study.
Nangaku M; Takama H; Ichikawa T; Mukai K; Kojima M; Suzuki Y; Watada H; Wada T; Ueki K; Narita I; Kashihara N; Kadowaki T; Hase H; Akizawa T
Nephrol Dial Transplant; 2023 May; 38(5):1204-1216. PubMed ID: 36002026
[TBL] [Abstract][Full Text] [Related]
11. Bardoxolone methyl and kidney function in CKD with type 2 diabetes.
Pergola PE; Raskin P; Toto RD; Meyer CJ; Huff JW; Grossman EB; Krauth M; Ruiz S; Audhya P; Christ-Schmidt H; Wittes J; Warnock DG;
N Engl J Med; 2011 Jul; 365(4):327-36. PubMed ID: 21699484
[TBL] [Abstract][Full Text] [Related]
12. Effects of Bardoxolone Methyl on Magnesium in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Rizk DV; Silva AL; Pergola PE; Toto R; Warnock DG; Chin MP; Goldsberry A; O'Grady M; Meyer CJ; McCullough PA
Cardiorenal Med; 2019; 9(5):316-325. PubMed ID: 31170712
[TBL] [Abstract][Full Text] [Related]
13. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
[TBL] [Abstract][Full Text] [Related]
14. Effects of NRF2 polymorphisms on safety and efficacy of bardoxolone methyl: subanalysis of TSUBAKI study.
Ikejiri K; Suzuki T; Muto S; Takama H; Yamawaki K; Miyazawa T; Urakawa I; Aoki Y; Otsuki A; Katsuoka F; Kinoshita K; Nangaku M; Akizawa T; Yamamoto M
Clin Exp Nephrol; 2024 Mar; 28(3):225-234. PubMed ID: 37962746
[TBL] [Abstract][Full Text] [Related]
15. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
[TBL] [Abstract][Full Text] [Related]
16. The CARDINAL Trial of Bardoxolone Methyl in Alport Syndrome: When Marketing Interests Prevail over Patients Clinical Needs.
Ruggenenti P
Nephron; 2023; 147(8):465-469. PubMed ID: 36731435
[TBL] [Abstract][Full Text] [Related]
17. Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.
Himmelfarb J; Tuttle KR
N Engl J Med; 2014 May; 370(18):1768-9. PubMed ID: 24804308
[No Abstract] [Full Text] [Related]
18. Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.
Ellison DH
N Engl J Med; 2014 May; 370(18):1768. PubMed ID: 24785223
[No Abstract] [Full Text] [Related]
19. Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.
Molnár GA; Kovács T; Wittmann I
N Engl J Med; 2014 May; 370(18):1767-8. PubMed ID: 24785222
[No Abstract] [Full Text] [Related]
20. Bardoxolone methyl in type 2 diabetes and advanced chronic kidney disease.
Chartoumpekis DV; Sykiotis GP
N Engl J Med; 2014 May; 370(18):1767. PubMed ID: 24785221
[No Abstract] [Full Text] [Related]
[Next] [New Search]
